Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Rare Community Profiles: What’s Your SMthing?: Pam’s Efforts to Create a Culture of Support and Awareness for Systemic Mastocytosis
    source: shutterstock.com

    Rare Community Profiles: What’s Your SMthing?: Pam’s Efforts to Create a Culture of Support and Awareness for Systemic Mastocytosis

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: What’s Your SMthing?: Pam’s Efforts to Create a Culture of Support and Awareness for Systemic Mastocytosis
    Rare Community Profiles: Mahnaz Asgharnejad Discusses Data on Soticlestat for LGS and Dravet Syndrome
    source: shutterstock.com

    Rare Community Profiles: Mahnaz Asgharnejad Discusses Data on Soticlestat for LGS and Dravet Syndrome

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: Mahnaz Asgharnejad Discusses Data on Soticlestat for LGS and Dravet Syndrome
    Utah Researcher is Screening Thousands of Drugs to Identify Potential SYNGAP1 Treatment
    nuzree / Pixabay

    Utah Researcher is Screening Thousands of Drugs to Identify Potential SYNGAP1 Treatment

      It can be undoubtedly difficult to identify therapies for rare diseases. Between the cost of research, the small population sizes, and the time required, the drug development process can…

    Continue Reading Utah Researcher is Screening Thousands of Drugs to Identify Potential SYNGAP1 Treatment
    ASCO: NALIRIFOX Improves Survival in Patients with Previously Untreated Metastatic Pancreatic Cancer
    https://unsplash.com/photos/tV-RX0beDp8

    ASCO: NALIRIFOX Improves Survival in Patients with Previously Untreated Metastatic Pancreatic Cancer

      The American Society of Clinical Oncology (ASCO) held its Annual Meeting from May 31 - June 4, 2023. During the meeting, attendees discussed a variety of oncological topics, trends,…

    Continue Reading ASCO: NALIRIFOX Improves Survival in Patients with Previously Untreated Metastatic Pancreatic Cancer
    ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation
    Photo by Robina Weermeijer on Unsplash

    ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation

      In May 2023, Pharmaceutical Technology reported that INO-3107, a DNA medicine vaccine candidate developed by biotechnology company Inovio Pharmaceuticals (“Inovio”), received Orphan Drug designation from the European Commission. INO-3107…

    Continue Reading ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation
    Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link
    source: shutterstock.com

    Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link
    Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication
    source: shutterstock.com

    Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication

    TransCode Therapeutics, Inc. (“TransCode”) was founded with a mission to revolutionize the cancer treatment landscape and improve patient outcomes. The company is currently working to uphold this mission through the…

    Continue Reading Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication
    Rare Community Profiles: Shantel S. and Shriners Children’s are Transforming the Way We Understand Arthrogryposis Multiplex Congenita (AMC)
    https://pixabay.com/en/book-heart-love-grains-sand-sea-2115176/

    Rare Community Profiles: Shantel S. and Shriners Children’s are Transforming the Way We Understand Arthrogryposis Multiplex Congenita (AMC)

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: Shantel S. and Shriners Children’s are Transforming the Way We Understand Arthrogryposis Multiplex Congenita (AMC)
    RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy
    source: pixabay.com

    RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

      Gene therapy has the potential to improve outcomes among individuals across various disease spectrums. In the case of clinical-stage biotechnology company Rocket Pharmaceuticals, the company is working to develop…

    Continue Reading RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

    Enrollment Complete in ARO-APOC3 Trial for Familial Chylomicronemia Syndrome

      Right now, there are insufficient treatment options for familial chylomicronemia syndrome (FCS). Unfortunately, this means that individuals living with this rare genetic disease are left without much assistance. The…

    Continue Reading Enrollment Complete in ARO-APOC3 Trial for Familial Chylomicronemia Syndrome